| abstract |
Formulations comprising therapeutically effective amounts of ambrisentan or a pharmaceutically acceptable salt thereof and tadalafil or a pharmaceutically acceptable salt thereof and methods for treating and / or preventing pulmonary hypertension by administration of the formulations. Claim 1: A pharmaceutical formulation characterized in that it comprises : a therapeutically effective amount of a selective type A endothelin receptor (ERA) antagonist that is selected from the group consisting of ambrisentan, sitaxsentan and pharmaceutically acceptable salts thereof, and a therapeutically effective amount of a phosphodiesterase inhibitor of type 5 (PDE5) which is selected from the group consisting of sildenafil, tadalafil, vardenafil and pharmaceutically acceptable salts thereof, where the weight ratio between the selective ARA type A and the PDE5 inhibitor is within the range between approximately 1: 1 and approximately Ent 1:10. Claim 14: The pharmaceutical formulation of claim 1, characterized in that it further comprises a third active agent comprising at least one drug that is selected from the group consisting of prostanoids, PDE5 inhibitors other than tadalafil, different endothelin receptor antagonists of ambrisentan, calcium channel blockers, diuretics, anticoagulants, oxygen and combinations thereof. |